Repurposed drug treats severe Covid-19 pneumonia
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe Covid-19 pneumonia in a recent clinical trial.
The drug, dornase alfa, could be used to treat other respiratory infections, according to the data from researchers at UCL, UCLH and the Francis Crick Institute.
The study found that dornase alfa reduced hyper-inflammation in Covid-19 pneumonia patients, which occurs when the body’s immune system reacts too strongly and can lead to tissue damage and death.
The next step will be to conduct larger clinical trials, with the ultimate goal of approving dornase alfa for wider use.
As well as Covid-19, it has the potential to treat other respiratory infections such as those caused by influenza or bacterial pneumonia, and even other lung diseases such as pulmonary fibrosis.
33% reduction in systemic inflammation
In this study, researchers set out to assess whether dornase alfa could be used to improve outcomes for patients admitted to hospital with severe Covid-19 pneumonia who required oxygen.
Out of 39 participants, 30 were randomised to receive twice-daily treatment with nebulised dornase alfa in addition to best available care (BAC) which included dexamethasone.
Patients treated with dornase alfa had a 33% reduction in systemic inflammation on top of the reduction provided by dexamethasone, as measured by C-reactive protein (CRP) levels in the blood over seven days or until they were discharged from hospital.
Dr Venizelos Papayannopoulos, senior author of the study from the Francis Crick Institute, said: “Dexamethasone…isn’t suitable for some patients, such as those with diabetes, those that do not require oxygen, and in very severe cases it may not be enough. Dornase alfa can be used to treat a wider variety of patients and gets right to the heart of the inflammatory response. Based on these results, we think it will be a valuable tool for tackling severe Covid-19 illness.”
Patients treated with dornase alfa were also more likely to need less oxygen and be discharged sooner compared to patients who received BAC.
Professor Joanna Porter, first author of the study from UCL Medicine and UCLH, said: “If we can help patients recover more quickly and get home sooner, this would be great for them and also help to reduce pressure on the NHS. I’m optimistic that dornase alfa will have applications for treating other respiratory infections, and acute exacerbations of other chronic lung diseases, such as pulmonary fibrosis, that may share mechanisms with severe Covid-19.”
Diana Spencer, Senior Digital Content Editor, DDW
